3/9
02:46 pm
edit
Editas Medicine (EDIT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $3.50 price target on the stock.
Low
Report
Editas Medicine (EDIT) had its "buy" rating reaffirmed by Chardan Capital. They now have a $3.50 price target on the stock.
3/9
02:21 pm
edit
Rating for EDIT
Low
Report
Rating for EDIT